Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2650 - Neuroendocrine carcinoma of the urinary bladder: a large analysis of the French GETUG consortium


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Tumour Site

Neuroendocrine Neoplasms


Marine Sroussi


Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283


M. Sroussi1, M. Lorcet2, M.P. Tardy3, M. Guerin4, F. Estrade5, R. Delva6, P. Barthelemy7, P. Lavaud8, Y. Neuzillet9, N. Penel10, N. Houede11, D. Pouessel12, E. Mussat13, M. Gross Goupil14, H. Gauthier15, A. Gobert16, O. Huillard17, Y. Allory18, R. Elaidi1, S. Oudard1

Author affiliations

  • 1 Medical Oncology Department, HEGP - European Georges Pompidou Hospital, 75015 - Paris/FR
  • 2 Medical Oncology Department, Léon Bérard Center, 69008 - Lyon/FR
  • 3 Medical Oncology Department, Antoine Lacassagne Center, 6100 - Nice/FR
  • 4 Medical Oncology Department, Paoli Calmettes Insitute, 13274 - Marseille/FR
  • 5 Medical Oncology Department, Eugène Marquis Center, 35042 - Rennes/FR
  • 6 Medical Oncology Department, Paul Papin Center, 49100 - Angers/FR
  • 7 Medical Oncology Department, University Hospital Center, 67000 - Strasbourg/FR
  • 8 Medical Oncology Department, Gustave Roussy Institute, 94800 - Villejuif/FR
  • 9 Urology Department, Hopital Foch, 92151 - Suresnes/FR
  • 10 General Oncology Department, Oscar Lambret Center, 59020 - Lille/FR
  • 11 Medical Oncology Department, Gard Cancerology Department, 30029 - Nimes/FR
  • 12 Medical Oncology Department, IUCT Oncopole, 31100 - Toulouse/FR
  • 13 Medical Oncology Department, Henri Mondor Hospital, 94010 - Creteil/FR
  • 14 Medical Oncology Department, St. André Hospital, 33000 - Bordeaux/FR
  • 15 Medical Oncology Department, St Louis Hospital, 75010 - Paris/FR
  • 16 Medical Oncology Department, Salpétrière Hospital, 75013 - Paris/FR
  • 17 Medical Oncology Department, Cochin Hospital, 75679 - Paris/FR
  • 18 Pathology Department, Curie Institute, 92210 - Saint-Cloud/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2650


Neuroendocrine carcinoma of the urinary bladder (NCUB) is a rare malignancy, accounting for <1% of bladder cancers. Despite high sensitivity to platinum-based chemotherapy (CT), prognosis remains poor.


We retrospectively reviewed patients treated for NCUB in 18 French institutions to determine clinical/biologic characteristics, treatment efficacy and outcomes. Patient characteristics, treatment, follow-up and histological data were obtained from medical records. Tissue samples were pooled for further biological analyses.


From 1992 to 2017, we reviewed 234 NCUB cases (84% male, age 31–93 [median 67] years, ECOG PS 0–3 [median 1]). Small cell carcinoma was found in 47% of patients and large cell carcinoma in 9%; urothelial carcinoma was present in 51% of patients. Hematuria (71%) and pain (19%) were the main symptoms. Main metastatic sites at diagnosis of metastatic disease were lymph node (76%), liver (42%), bone (42%), pelvic recurrence (33%), lung (19%) or brain (12%). Of 230 patients evaluable for staging at diagnosis, 168 had stage I–III disease: stage I (3%), II (20%), III (34%), not evaluable (16%). They were treated with neoadjuvant CT (49%; mainly based on a platinum-based agent + etoposide [85%]), surgery (74%), radiotherapy (24%), and/or adjuvant CT (24%). Ninety-nine patients (59%) had metastatic recurrence. Median time to relapse was 4 months, disease-free survival was 14 months (95% confidence interval [CI] 12–18]), and median overall survival (mOS) was 28 months (95% CI 20–32). Of 62 patients (27%) with metastases at diagnosis, first-line CT was based on platinum + etoposide (81%), platinum + other drug (15%), or taxanes (4%). For these patients, median progression-free survival (mPFS) was 7 months (95% CI 4–9). Only 28 patients had second-line CT with mPFS of 5.2 months and mOS of 11 months (95% CI 8–15).


This is, to our knowledge, the largest cohort of NCUB patients studied to date. Data emphasize the heterogeneity and aggressiveness of this disease. Future studies should investigate disease biology and the activity of targeted therapies in NCUB. Molecular characteristics based on tumor tissue analysis are underway.

Clinical trial identification

Legal entity responsible for the study

HEGP (European Georges Pompidou Hopsital).


Pierre Fabre.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.